Leukemia Department - Clinical Trials - M. D. Anderson Cancer Center

Clinical Trials Title Graphic

Leukemia Department Home

Disease Information

Faculty & Staff

Fast Track Clinic

Clinical Trials

Leukemia Insights Newsletter

Patient's Corner

Leukemia Resources & Links

Ride for Leukemia Research

Last Updated: 4/28/09

Leukemia Clinical Trials are Grouped by Disease Type:

Phase I Agents

Myelodysplastic Syndromes

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia

Myeloproliferative Diseases

line

Phase I Agents

HuM195/rGel (AML,MDS,CML) (DM98-342)
BAY-43-9006 (ALL, AML, MDS, CML) (2004-0702)
Clofarabine + Cytoxan (ALL) (2005-0552)
5 AZA-2 Deoxycytidine (ALL) (2005-0895)
AT9283 (CML, MDS, MPD) (2006-0177)
INNO-406 (ALL, CML) (2006-0278)
Gimatecan (MDS) (2006-0943)
FAO (AML, MDS) (2006-1089)
SAHA + DAC (AML, MDS) (2006-1096)
Oral Azacitidine (AML, MDS) (2007-0405)
RO5045337 (ALL, AML, CLL, CML) (2007-0408)
OPB-31121 (ALL, AML, MDS, CLL, CML) (2007-0488)
XL228 (CML, ALL) (2007-0502)
Bendamustine (ALL, AML, MDS, CML) (2007-0634)
ARRY-520 (AML, MDS, CML) (2007-0879)
SB1518 (AML, MDS, CML, MPD) (2008-0032)
AP24534 (2008-0046)

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated

Hyper-CVAD + Dasatinib (2006-0478)
Hyper-CVAD + Rituximab (ID02-229)
Modified Hyper-CVAD +/- Rituximab (ID02-230)
Hyper-CVAD + Nelarabine (2006-0328)

Salvage Programs

Hyper-CVAD + Dasatinib (2006-0478)

SKI-606 (2005-0813)

INNO-406 (2006-0278)
Dasatinib (2007-0606)
PHA-739358 (2007-0939)
ap24534 (2008-0046)
Marqibo (Liposomal Vincristine) (2006-1109)
Clofarabine + Cytoxan (2005-0552)
5 AZA-2 Deoxycytidine (2005-0895)
INCB018424 (2007-0925)
Augmented Hyper-CVAD (ID03-0166)
MOAD (2008-0267)

Supportive Care

Actonel vs. Placebo for Prevention of Bone Loss (ID03-0124)
Tight Control of Glucose During Hyper-CVAD (2004-0107)
White Blood Cell Transfusion (2007-0797)

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

Fludarabine, Ara-C, G-CSF and Gemtuzumab Ozogamicin (2007-0147)
ATRA and arsenic +/- gemtuzumab and theophylline (2006-0706)
Ida + Ara-C + SAHA (2007-0835)
Ida + Ara-C + Sorafenib (2006-0977)
Ida + Ara-C (2006-0813)
DAC + Gemtuzumab Ozogamicin (2007-0882)
Clofarabine + Ara-C + DAC (2007-0039)
DAC +/- Valproic Acid (2006-0686)
Oral Sapacitabine (2007-0727)
DAC + Mylotarg (2007-0882)
SNS-595 (2007-0965)
Bendamustine (2007-0634)
CPX-351 vs 3+7 (2008-0603)
Randomized study of DAC vs observation as maintenance therapy (2006-0358)
DAC vs. supportive care or LD Ara-C (2005-0647)

Salvage

Oral Tamibarotene (2007-0512)
CA vs CI vs CIA (ID03-0181)
Oral Sapacitabine (2007-0727)

DAC + Gemtuzumab Ozogamicin (2007-0882)

CPX vs standard salvage therapy (2008-0679)

Revlimid (2006-0293)

Ida + Ara-C + SAHA (2007-0835)

INCB018424 (2007-0925)
ly2181308 (2007-0707)
DT388IL3 (2008-0313)
FAO (2006-1089)
Randomized Clofarabine + Ara-C vs Ara-C (2006-0069)
Bendamustine (2007-0634)

line

Myelodysplastic Syndrome (MDS)

Low Risk

Thymoglobulin + CSA in aplastic anemia and hypoplastic MDS (2005-0115)

Ph II DACOGEN (Decitabine) (2007-0883)
Ph II Revlimid + Darbepoetin alfa (2006-0657)
Ph I Oral Azacitidine (2007-0405)
AMG 531 in patients receiving Hypomethylating Agents (2006-0722)
Ph II Romiplostim Treatment of Thrombocytopenia (2008-0249)
Ph I JNJ-26481585 (2008-0245)
Ph II Ezatiostat Hydrochloride (Telintra) (2008-0081)

IPSS Int-1

Ph II DACOGEN (Decitabine) (2007-0883)
Ph I Gimatecan (2006-0943)
Ph II LD DAC +/- VA (2006-0686)
Ph II Oral Clofarabine (2005-0536) or IV Clofarabine (2005-0535)
Ph I Oral Azacitidine (2007-0405)
AMG 531 in patients receiving Hypomethylating Agents (2006-0722)
Ph II Romiplostim Treatment of Thrombocytopenia (2008-0249)
Ph I JNJ-26481585 (2008-0245)
Ph II Ezatiostat Hydrochloride (Telintra) (2008-0081)

IPSS int-2 or high

Ph II Oral Sapacitabine (2007-0727)
Ph II Oral Clofarabine (2005-0536) or IV Clofarabine (2005-0535)
Ph II LD DAC +/- VA (2006-0686)
DAC + Gemtuzumab Ozogamicin (2007-0882)
Lenalidomide for any chromosome 5 abnormality (2006-0293)
Ph I Gimatecan (2006-0943)
Clofarabine + Ara-C + DAC (2007-0039)
Ph I Oral Azacitidine (2007-0405)
Ph I/II Ida + Ara-C + Sorafenib (2006-0977)
Ph II Ida + Ara-C + SAHA (2007-0835)
DT388IL3 (2008-0313)
Ph I JNJ-26481585 (2008-0245)

CMML
With < 10% blasts

Ph I BAY-43-9006 (2004-0702)

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Ph IB Autologous CLL B Cells Transduced to Express ISF 35 (2007-0095)

Untreated - all stages

FCR (2008-0431)
Lenalidomide (2006-0715)

Mimimal Residual Disease

Rituximab + Alemtuzumab (2006-0767)

Prior Therapy

FCR + Bevacizumab (2005-0992)

HuMax-CD20 (2006-0314)

Lenalidomide + Rituximab (2007-0208)

OFAR 2 (2006-1026)

ABT-263 (2007-0096)

8-Cloro-Adenosine (2004-0144)

GS9219 (2007-0087)

Dasatinib (BMS-354825) (2005-0497)

5-Aza (2006-0428)

Two Lenalidomide dose regimens (2006-0725)

FAMP + CTX + Rituxan (ID99-338)

Lumiliximab + FCR vs FCR (2006-0789)

RO5045337 (2007-0408)

Alemtuzumab (2007-0626)

Other Studies

2CDA + Rituximab in Hairy Cell Leukemia (2004-0223)

Campath + Pentostatin in T-Cell Neoplasms (2004-0408)

line

Chronic Myelogenous Leukemia (CML)

Chronic phase

BMS-354825 (2005-0422)

Oral AMN107 (2005-0048)

Bosutinib vs Imatinib (2007-0709)

SKI-606 (2005-0813)

Homoharringtonine (CGX635) (2006-0926)

XL228 (2007-0502)

AP24534 (2008-0046)

Dasatinib (2007-0606)

INCB018424 (2007-0925)

Ph I INNO-406 (2006-0278)

Accelerated Phase

SKI-606 (2005-0813)

XL228 (2007-0502)

PHA-739358 (2007-0939)

AP24534 (2008-0046)

Homoharringtonine (CGX635) (2006-0926)

INCB018424 (2007-0925)

Ph I INNO-406 (2006-0278)

SB1518 (2008-0032)

Blastic Phase

SKI-606 (2005-0813)

Homoharringtonine (CGX635) (2006-0926)

XL228 (2007-0502)

AP24534 (2008-0046)

PHA-739358 (2007-0939)

INCB018424 (2007-0925)

Ph I INNO-406 (2006-0278)

SB1518 (2008-0032)

Imatinib failures with T315l mutations (any stage)

Homoharringtonine (CGX0635) (2006-0192)

INCB018424 (2007-0925)

PHA-739358 (2007-0939)

Minimal Residual Disease

Dasatinib + Ipilimumab (2008-0157)

line

Myeloproliferative Diseases

INCB018424-251 - JAK2 Oral (CIMF) (2007-0169)

TG101348 (CIMF) (2007-0837)

SB1518 (2008-0032)

PEG IFN-alpha2a (PV, ET) (DM03-0109)

2CDA + Ara-C (HES) (DM97-232)

RAD001 (SM) (2006-0759)

©2009 The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030
1-800-392-1611 (USA) / 1-713-792-6161 (7)

Legal Statements | Become a Patient | Make a Donation | Subscribe to Newsletters |